Skip to content
Eikon Therapeutics, Inc.
 logo

Eikon Therapeutics, Inc.

EIKN

Eikon Therapeutics, Inc. is a biotechnology company in the healthcare sector trading on XNAS, led by CEO Roger Perlmutter, with a market cap of $521.4M.

Market cap
$521.35M-32.8%

Table of contents

Earnings

Next report

Aug 10, 2026 (in a month)
EPS estimate-$1.61

Financials

Q4 2025

Income statement

See full
Operating income-$87.3M-22.3%
Net income-$83.0M-21.6%
EPS (diluted)-$2.46+90.9%

Balance sheet

See full
Cash & equivalents$161.2M-21.2%
Total debt$254.8M
Total equity$550.7M+186%
Total assets$850.8M

Cash flow

See full
Operating cash flow-$89.8M-64.7%
CapEx$262.0K-98.8%
Free cash flow-$90.1M-17.1%

Profile

Listed2026
CEORoger Perlmutter
FilingsSEC EDGAR

Questions, answered.

What is Eikon Therapeutics, Inc. 's market cap?
Eikon Therapeutics, Inc. (EIKN) has a market capitalization of $521.4M and trades on XNAS.
Where is Eikon Therapeutics, Inc. headquartered?
Eikon Therapeutics, Inc. is headquartered in United States of America. It has been publicly traded since 2026.